corpor updat backdrop anoth preclin transact
gener forma cash includ proce
februari buy fein transact
includ up-front payment expect close
forma cash includ proce
februari buy fein transact
includ up-front payment expect
close
compel preclin licens agreement overlook
platform februari sangamo zfn gene regul
capabl got nice nod approv up-front deal
buy fein compris licens fee
million share sangamo stock
 premium market base sangamo februari
close price sangamo elig receiv
potenti mileston well royalti potenti net commerci
sale note prior announc short interest stood
share repres day trade volum
sangamo trade ev collabor aim
leverag sangamo zfn aav-deliveri platform develop gene
regul therapi neuromuscular/neurolog indic biogen
gain exclus global right tauopathi includ
alzheim diseas synucleinopathi includ pd
earli development cycl preclin data indic
act intend decreas tau protein nhp
brain decreas a-synuclein neuron cell cultur
natur medicin articl zfn-tf reduc mutant htt
transcript mous striatum approxim doi
expect enter
clinic respect exclus right
nomin nine addit undisclos target target
select period five year sangamo would perform earli research
activ cost would share compani biogen
would assum respons cost investig
interact global commerci transact nice
shot arm alreadi well-fund extens partner
franchis begin resembl
rate procliv licens asset rel earli stage
transfer clinical/commerci risk partner given pro forma
cash approxim anticip clinic regulatori
commerci mileston rate phase
readi hope see sangamo retain ownership futur
number sangamo
report oper gain/ loss vs
estim ep
vs estim discrep
due fact includ mileston
ind transfer mileston associ
dose first subject phase clinic
trial partner sanofi sni rate sangamo exit
cash along transact
impli pro forma cash posit excess
suffici fund oper forese futur
project estim oper loss
gaap ep
definit distribut analyst rate analyst certif disclosur pleas refer page report
addit pipelin aav-bas gene therapi fabri diseas evalu staar trial
current screen patient six site recent open first european site although screen
failur associ nab stymi enrollment/dos preliminari data expect
first patient dose ex-vivo gene-edit modal scd mechan
phase studi treg cell therapi evalu phase steadfast trial
renal transplant receiv regulatori approv clinic trial applic eu unfortun
action near-term stock appreci perspect sentiment remain leverag updat hemophilia
phase program note progress phase registr studi run partner
recent updat includ patient follow-up demonstr robust fviii activ four five patient
remain normal threshold regulatori approv anoth clinic updat timepoint
would help distinguish valrox biomarin rate former maintain high fviii unlik
latter timepoint follow-up subject point stabl fviii activ anticip
hemophilia commun wait commerci product superior durabl render valrox clinic
lead inconsequenti altern follow decay kinet similar valrox analysi point year durabl
would nearli doubl expect valrox anticip dose first subject
sanguin thesi especi comparison valrox base potenti doubl durabl superior
liver transduct effici vs cleaner safeti profil date afford payer physician
strong rational choos valrox view note biomarin exclus igg patient
phase potenti benefit remain patient less like therefor amen
treatment given nab potenti mutual exclus impli subject experienc
diminish clinic benefit follow valrox could becom futur candid estim recal progress
entitl sangamo least mileston payment along double-digit percentag world-wide royalti
valuat reiter buy rate price target deriv risk-adjust sum-of-the-part analysi
drive dcf model dcf base beta termin growth rate risk premium
calcul wacc tax rate begin fy target primarili leverag
repres approxim rnpv per share recal progress entitl sangamo least
mileston payment along double-digit percentag world-wide royalti remain target
reflect contribut probability-adjust mileston payment rnpv current partnership
sanofi gilead rate unencumb fabri program rnpv sanofi-partn
rnpv remain assign develop scd note
core vivo zfn gene edit technolog recalibr rare genet diseas along implic ex vivo
applic cell current exclud rnpv base preclin statu risk could materi
impair bullish thesi includ reimburs regulatori clinic manufactur financ safeti
unknown durabl gene therapi gene edit could impact reimburs price note issu
pertain public percept gene therapi especi gene edit addit risk factor could neg
impact commerci adopt henc futur sale cash flow estim
discount tax non-cash work cash flow valu cash valu total per risk-fre rate yr premium equiti debt growth inc
thousand except per share data
net revenu research collabor
good sold
research develop
gener administr
interest incom expens net
total incom expens
loss incom tax
net loss attribut non-control interest
thousand except per share data
flow oper activ
amort discount market secur
gain free share
build-to-suit leas net loss leas termin
prepaid expens asset
account payabl accru liabil
accru compens employe benefit
long-term portion leas liabil
net cash provid use oper activ
flow invest activ
purchas properti equip invest
purchas matur market secur
acquisit net cash acquir
net cash provid use invest activ
flow financ activ
proce public offer common stock net issuanc cost
tax paid relat net share settlement equiti award
proce issuanc common stock
net cash provid use financ activ
effect chang foreign exchang rate
net increas decreas cash/cash equival
 equival begin period
 equival end period
thousand except per share data
cash equival
prepaid expens current asset
properti equip net
liabil stockhold equiti
account payabl accru liabil
accru compens employe benefit
long-term portion leas liabil build-to-suit leas oblig
accumul comprehens loss
total liabil stockhold equiti
outlook ratio analysi enterpris valu
burn period cash oper
total cash cash equival interest receiv
period cash remain
ebitda sale
return asset roa
return equiti roe
materi confidenti intend use institut account defin finra rule may also
privileg otherwis protect work product immun legal rule receiv mistak pleas let
us know email repli delet system may copi messag
disclos content anyon integr secur messag guarante internet
 wainwright co llc rate wainwright employ three tier rate system evalu
potenti return risk associ own common equiti share rate firm expect return given
equiti measur rel basi compani sector price object calcul estim
potenti movement price given equiti could reach provid certain target met defin time horizon
price object subject extern factor includ industri event market volatil
market outperform buy common stock compani expect outperform passiv index compris
common stock compani within sector
market perform neutral common stock compani expect mimic perform passiv index
compris common stock compani within sector
market under-perform sell common stock compani expect under-perform passiv index compris
common stock compani within sector
rate price target histori inc sgmo-u
rate price target histori inc biib-u
relat compani mention report
invest bank servic includ limit act manager/co-manag underwrit placement
secur act financi advisor and/or provid corpor financ capit markets-rel servic compani
one affili subsidiari within past month
distribut rate tabl februari
 wainwright co llc firm member finra sipc regist broker-deal
debjit chattopadhyay earl desouza certifi view express report accur reflect person
view subject secur issuer discuss part compens directli
indirectli relat specif recommend view express research report neither
member household offic director advisori board member compani
none research analyst research analyst household financi interest secur sangamo
therapeut inc inc includ without limit option right warrant futur long short posit
februari neither firm affili benefici class common equiti secur
inc inc
neither research analyst firm know reason know materi conflict interest time
public research report
research analyst princip respons prepar report receiv compens base upon
specif invest bank servic transact compens base factor includ total revenu profit
firm substanti portion deriv invest bank servic
firm affili receiv compens inc inc invest bank
servic within twelv month seek compens compani mention report invest
bank servic within three month follow public research report
firm make market sangamo inc inc date research report
secur compani discuss report may unsuit investor depend specif invest
object financi posit past perform guarante futur result report offer inform
purpos constitut offer solicit buy sell secur discuss herein jurisdict
would prohibit research report intend provid tax advic use provid tax advic
person electron version wainwright co llc research report made avail client simultan
part report may reproduc form without express permiss wainwright co llc addit
 wainwright co llc provid individu tailor invest advic research report research report
intend provid person invest advic take account specif invest object financi
situat particular need specif person investor seek financi advic regard appropri
invest financi instrument implement invest strategi discuss recommend research report
 wainwright co llc affili salespeopl trader profession may provid oral written market
commentari trade strategi reflect opinion contrari opinion express research report
 wainwright co llc affili offic director employe exclud analyst time time
long short posit act princip buy sell secur deriv includ option warrant
thereof cover compani refer research report
inform contain herein base sourc believ reliabl guarante us
accur purport complet statement summari avail data compani industri secur
discuss report opinion estim includ report constitut analyst judgment date
report subject chang without notic
secur financi instrument discuss research report may lose valu insur feder
deposit insur corpor subject invest risk includ possibl loss princip amount invest
